Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting
Step-up dose titration lowered GI side effects while maintaining clinical activity
Majority of patients completing 13 weeks of treatment demonstrated significant improvement on at least 2 measures of disease activity
Conference Call and Webcast today at
SOUTH SAN FRANCISCO, Calif.,
“We are thrilled to share these additional promising data with KZR-616, our novel immunoproteasome inhibitor, at the
The primary objective of the Ph1b portion of MISSION is to assess safety and tolerability. Secondary objectives include evaluating pharmacokinetics (PK), pharmacodynamics (PD), and selecting dose levels for the Phase 2 trials. Several exploratory efficacy measures are also being assessed: Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), Cutaneous Lupus Erythematosus Severity Index-Activity (CLASI-A), Tender and Swollen Joint Counts (TJC/SJC), and Physician Global Assessment (PhGA)/Patient Global Assessment (PtGA)/Patient Assessment of Pain (PtP).
As of the
An infographic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3ee3c805-5cae-4a27-888d-b98be6676880
Updated data suggest KZR-616 continues to show a differentiated safety profile from non-specific proteasome inhibitors and, importantly, that a dose of 60 mg is well-tolerated when administered via step-up dosing. Additionally, KZR-616 appears to exhibit broad immunomodulatory activity and has the potential for limited immunosuppressive side effects.
The updated results are detailed below:
- Step-up dosing exhibits improved tolerability
- Nausea and vomiting were reported in <20% of patients following step-up dosing vs. 100% of patients receiving an initial dose of 60 mg
- Discontinuation rates declined substantially, from 38% to 20%, for patients receiving step-up dosing
- Patients receiving KZR-616 largely avoided toxicities associated with approved non-specific proteasome inhibitors
- No cases of peripheral neuropathy
- No prolonged constitutional adverse events, such as fatigue and myalgia
- No laboratory abnormalities lasted longer than seven days, and only one hematologic event was noted during the period (neutropenia)
- The incidence of serious (≥ Grade 3) and overall infections was low (4% and 22%, respectively)
- One additional SAE (systemic inflammatory response) was reported during the study period; the patient resumed dosing and completed treatment
- Consistent PK and PD was seen across all dose levels, with target levels of immunoproteasome inhibition achieved at each dose level
- Broad and consistent improvements were seen across multiple measures and assessments of disease activity. Of 16 patients completing 13 weeks of treatment (Cohorts 1, 2, and 2a):
- SLEDAI-2K: 75% had a decrease ≥2 points
- CLASI-A: 67% with CLASI-A ≥4 at BL had a decrease ≥4 points
- TJC/SJC: 56% had ≥50% improvement on either TJC or SJC
- PhGA/PtGA/PtP: 50%, 75%, and 69% had a ≥10-point reduction, respectively
Based on these results, the Phase 2 portion of MISSION will evaluate doses of 30, 45 and 60mg in patients with lupus nephritis (LN). Additionally, 30 and 45 mg doses are being evaluated in Phase 2 studies in patients with dermatomyositis/polymyositis (PRESIDIO) and autoimmune hemolytic anemia/immune thrombocytopenia (MARINA).
“I’m enthusiastic about this novel mechanism that has the potential to transcend traditional plasma-cell depleting therapies and inhibit multiple sites of inflammation. Severe autoimmune diseases, such as lupus and lupus nephritis can be life threatening, and effective treatment options are profoundly needed,” said Richard Furie, MD, Chief,
In addition to the Ph1b update from MISSION, Kezar presented three other posters on KZR-616 at the conference. First, biomarker analyses of patients treated with KZR-616 demonstrated a reduction in inflammatory gene signatures and an increase in genes involved in red blood cell production. Second, positive results were presented from a Phase 1 trial in healthy volunteers evaluating a simplified lyophilized formulation of KZR-616. Finally, preclinical data in a mouse model of LN showed decreased expression of several inflammatory and kidney tissue damage gene signatures and a similarity of the anti-inflammatory effects of KZR-616 in the mouse model and in treated patients.
Conference Call and Webcast Information
To access the live conference call via phone, dial 877-407-9711 (U.S. toll-free) or 412-902-1014 (toll). The conference ID number for the live call is 13696599. Additionally, a live webcast of the call will be available under the Events section of the Kezar’s Investor Relations (IR) site at http://investors.kezarlifesciences.com/events. A slide presentation will accompany the call and can be accessed via the weblink. An archived replay of the call will be available on the company’s IR site for 90 days following the live call.
KZR-616 is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Phase 1b clinical trial results in patients with systemic lupus erythematosus provide early evidence that KZR-616 potentially avoids adverse effects caused by currently marketed non-selective proteasome inhibitors, which we believe prevent them from being utilized as a chronic treatment in autoimmune disorders. Phase 2 trials have commenced for the treatment of lupus nephritis (MISSION), dermatomyositis and polymyositis (PRESIDIO), and autoimmune hemolytic anemia and immune thrombocytopenia (MARINA).
About the MISSION Study
The MISSION study (NCT03393013) is a Phase 1b/2 multi-center study in which patients receive weekly subcutaneous injections of KZR-616 for 13 weeks. The study consists of two parts. The Phase 1b portion is an open-label multiple dose escalation study to evaluate the safety and tolerability of KZR-616 in patients with SLE with and without nephritis. The Phase 2 portion is a randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of 30, 45 and 60 mg of KZR-616 in patients with active proliferative LN.
About Kezar Life Sciences
Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe autoimmune diseases, including systemic lupus erythematosus (SLE), lupus nephritis (LN), dermatomyositis (DM), polymyositis (PM), autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Additionally, Kezar has nominated KZR-261 as its first clinical candidate for the treatment of cancer from its protein secretion program and is undergoing IND-enabling studies for the program. For more information, visit www.kezarlifesciences.com.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “should,” “expect,” “believe” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the likelihood that data will support future development, the association of data with treatment outcomes, the design, progress, timing, scope and results of clinical trials, the anticipated timing of disclosure of results of clinical trials and the likelihood of obtaining regulatory approval of Kezar’s product candidates. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar’s filings with the
SVP, Strategy & External Affairs
Source: Kezar Life Sciences, Inc.